Effect of PPV on retinal vessel oxygen saturation

Article

PPV has been a major advancement in the treatment of retinal diseases, however, little is known about its effect on oxygen metabolism in retinal vessels. In this article, Dr Sin reveals the results of his pilot study examining the effect of PPV on the oxygen saturations in retinal vessels.

The retina has a high demand for oxygen and starvation of this element in retinal vessels is considered to be an important factor in certain diseases, such as diabetic retinopathy and glaucoma.1 To examine the effect of PPV on oxygen saturation in retinal vessels a new tool, oximetry,2 was employed, explained Dr Martin Šín (Department of Ophthalmology, University Hospital Olomouc, The Czech Republic) when discussing the initial reasoning behind his recent pilot study.3 "Our head of department, Professor J. Rehak, has been researching retinal vein occlusion for many years. In 2011, he bought an automatic retinal oximetry (Oxymap, Reykjavik, Iceland) device allowing us to investigate the oxygen saturation in retinal vessels," he said.

Investigating the influence of PPV

Oximetry was performed 24 hours before PPV and then ranging between 42 and 49 days after PPV, which was either 20G or sutureless 23G. Oxygen saturation levels were examined in both retinal arteries and veins and vessel segments of first or second degree were selected. These specific segments were analysed before and after PPV to determine whether there was any change or effect of the surgery on oxygen saturation. The comparison of this data was performed using two-tailed t-test.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.